Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Investor Presentation (October 2025)
26 slides from Amplia Therapeutics's investor presentation, Oct 14, 2025
Slide 1: Melbourne Investor Briefing
Melbourne Investor Briefing 14 October 2025 Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD ampliatx.com | @ampliatx 1
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operat
Slide 3: Executive Summary
EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer New trial of narmafotinib in pancreatic cancer now u
Slide 4: Company Summary
COMPANY SUMMARY ASX: ATX ATX Price and Volume - 12 months Share price $0.15 (14 Oct 2025) Share price range $0.049 - 0.42 (52 week low/high) Shares on issue 513.07M Market capitalization $77.0M (approx.) (14 Oct 2025) 4
Slide 5: Board + Management
BOARD + MANAGEMENT World-class experts BOARD SENIOR MANAGEMENT Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell Chris Burns* MB ChB MPP GAICD PhD LLB LLM (Lond) FAICD PhD GAICD Director CEO and MD Jason Lickliter Chair Director MBBS FRACP CMO Tim Luscombe BCom CA GIA(Cert) CFO * Co-R
Slide 6: Metastatic Pancreatic Cancer
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Other regimens 20% Most patients receive gemcitabine + Abraxane 5-FU treatments 2.2% or FOLFIRINOX Gem + Abraxane 46.4% or variations of these† 3% FOLFIRINOX 18.9% Gemcitabine 12.4% Me
Slide 7: Metastatic Pancreatic Cancer: Can narmafotinib improve response to chemotherapy?
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes Can narmafotinib improve response to chemotherapy? What about new treatments in development? 7
Slide 8: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR An Australian Discovery Drug discovered at Cooperative Research Centre for Cancer Therapeutics Government supported industry - academic partnership Focus on potential in treatment of solid cancers Excellent preclinical profile Drug-like properties P
Slide 9: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to proliferate Enhances act
Slide 10: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to proliferate Enhances act
Slide 11: The Amplia Advantage
THE AMPLIA ADVANTAGE Three critical features Efficacy Narmafotinib Tolerability Durability 11
Slide 12: ACCENT Trial in Pancreatic Cancer
ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea Intermittent dosing schedule OBJECTIVE narmafotinib To determine safety and efficacy of narmafotinib Gemcitabine + when added to standard of care Abraxane in newly diagnosed patients PRIMARY ENDPOINTS Safety, Tolerability ORR
Slide 13: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Median Progression Free Survival (mPFS) data All ACCENT patients @ 400 mg (n = 64) (20 Jul 2025) Determined at 7.6 months - substantially better than chemotherapy alone (5.5 months) Interim data with 17 patients on
Slide 14: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 17 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 15: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 17 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 16: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 17 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 17: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 17 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 18: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden Adverse Events (Grade 3 or above) Narmafotinib + Gem/Abr (ACCENT; N=55) Gem/Abr (MPACT; N=421) 40 30 20 10 0
Slide 19: ACCENT Trial Summary
ACCENT TRIAL SUMMARY On track to achieve trial goals Superior Efficacy Improved Durability Demonstrated Tolerability For full 55 patient cohort 7 patients on trial for >12 Excellent tolerability profile 1 CR months 17 PR (incl. 1 pCR) Minimal additional burden on Deep and sustained response the pati
Slide 20: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR Best-in-class profile Convenient to take Once a day oral dosing by capsule Storage at room temperature Safe to combine with other medicines No evidence of drug-drug interactions Evidence of FAK target engagement preclinically and in the clinic 20
Slide 21: AMPLICITY Trial in mPDAC
AMPLICITY TRIAL in mPDAC Phase 1b/2a study in the US and Australia Moving from intermittent to daily dosing OBJECTIVE To determine safety and efficacy of narmafotinib narmafotinib when added to FOLFIRINOX in newly diagnosed patients FOLFIRINOX To identify recommended phase 2 dose (RP2D) PRIMARY ENDP
Slide 22: AMPLICITY Trial
AMPLICITY TRIAL Phase 1b/2a study in Pancreatic Cancer in the US and Australia Objective To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed metastatic patients To identify recommended phase 2 dose (RP2D) www.amplicitytrial.com Primary Endpoints Safety, Toler
Slide 23: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. Preclinical data ACCENT study KRAS INHIBITORS RADIOTHERAPY Preclinical data, incl. Published data collaboration ANTIBODY DRU
Slide 24: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition provides benefit in multiple tumour types prostate cancer ovarian cancer melanoma breast cancer lung cancer colorectal cancer gastric cancer pancreatic cancer 24
Slide 25: Future Milestones
FUTURE MILESTONES Key deliverables ACCENT (NARMAFOTINIB + GEMCITABINE + ABRAXANE) Recruitment Response Topline Mature Trial Phase 2b/3 completed rate update data (PFS) data completion Initiation 2025 2026 2027 Trial Sites First patient Dose Complete dose Initiate 2 dose Complete dose Engagement dose
Slide 26: Thank You
THANK YOU Chris Burns PhD GAICD FAHMS chris@ampliatx.com Rhiannon Jones PhD GAICD rhiannon@ampliatx.com Amplia Therapeutics Limited ASX: ATX info@ampliatx.com ampliatx.com 26
Amplia Therapeutics — Investor Presentation (October 2025) on 6ix